Processa Pharmaceuticals (PCSA) Intangibles (2013 - 2022)
Processa Pharmaceuticals' (PCSA) quarterly Intangibles came in at $11.1 million in Q4 2022, up 37.27% YoY from $8.1 million in Q4 2021, and up 48.15% on a QoQ basis from $7.5 million in Q3 2022.
Processa Pharmaceuticals (PCSA) Intangibles (2013 - 2022) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 8 years of Intangibles data on file, last reported at $11.1 million in Q4 2022.
- Quarterly Intangibles rose 37.27% year-over-year to $11.1 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $11.1 million (up 37.27% YoY) and the FY2022 annual result came in at $11.1 million, up 37.27% from the prior year.
- Intangibles advanced to $11.1 million in Q4 2022, from $7.5 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $11.1 million in Q3 2018 to a low of $7.5 million in Q3 2022.
- A 5-year average of $9.3 million and a median of $9.2 million in 2020 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2019 — Intangibles slipped 11.01% — and 2022, when it jumped 37.27%.
- Tracing PCSA's Intangibles over 5 years: stood at $10.4 million in 2018, then retreated by 7.62% to $9.6 million in 2019, then retreated by 8.25% to $8.8 million in 2020, then declined by 8.93% to $8.1 million in 2021, then soared by 37.27% to $11.1 million in 2022.
- The last three Intangibles figures came in at $11.1 million (Q4 2022), $7.5 million (Q3 2022), and $7.7 million (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | - |
| 10 | Processa Pharmaceuticals | 5.78 Mn | 5.78 Mn | - | 472,003.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 11.06 Mn |
| Sep 30, 2022 | 7.47 Mn |
| Jun 30, 2022 | 7.66 Mn |
| Mar 31, 2022 | 7.86 Mn |
| Dec 31, 2021 | 8.06 Mn |
| Sep 30, 2021 | 8.25 Mn |
| Jun 30, 2021 | 8.45 Mn |
| Mar 31, 2021 | 8.65 Mn |
| Dec 31, 2020 | 8.85 Mn |
| Sep 30, 2020 | 9.05 Mn |
| Jun 30, 2020 | 9.24 Mn |
| Mar 31, 2020 | 9.44 Mn |
| Dec 31, 2019 | 9.64 Mn |
| Sep 30, 2019 | 9.84 Mn |
| Jun 30, 2019 | 10.04 Mn |
| Mar 31, 2019 | 10.24 Mn |
| Dec 31, 2018 | 10.44 Mn |
| Sep 30, 2018 | 11.06 Mn |
| Jun 30, 2018 | 10.82 Mn |
| Mar 31, 2015 | 1.61 Mn |